Protagen

The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.

The collaboration will use Protagen's SeroTag technology to predict patient response to immunotherapy treatment and to monitor patients for adverse effects.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.